Offers

Quote






























anonymous said:
Have they made offers since Dallas?
Click to expand...
yeah-if you are a twenty year old something that has been hit too many times in the head playing football, your offer is in the mail. Prediction: This company will be under government investigation within the year. Just based on their hiring choices. Don't stress if you didn't get an offer, this company is off to a very bad start by using very bad judgement. You are better off not being a part of the planned corruption.
 












But one of your boys is doing quite well!

Executive Profile
Paul Brannelly
Chief Financial Officer and Executive Vice President, Collegium Pharmaceutical, Inc.
Age Total Calculated Compensation This person is connected to 0 Board Members in 0 different organizations across 4 different industries.
42 $917,208
As of Fiscal Year 2015
Background
Mr. Paul Brannelly has been the Chief Financial Officer and Executive Vice President of Collegium Pharmaceutical, Inc. since February 9, 2015. Mr. Brannelly served as Senior Vice President of Finance & Administration at Karyopharm Therapeutics, Inc. from June 13, 2013 to August 2014. Mr. Brannelly served as the Principal Financial Officer and Principal Accounting Officer of Karyopharm Therapeutics, Inc. until August 2014 and its Secretary and Treasurer from July 2013 to August 2014. Prior to Karyopharm, Mr. Brannelly served as Vice President of Finance at Verastem, Inc., a biopharmaceutical company, from September 2011 to June 2013, Chief Financial Officer from November 2010 to September 2011, and as Treasurer and Secretary from November 2010 to June 2013. From January 2010 to September 2011, Mr. Brannelly held the position of Chief Financial Officer at the Longwood Fund. From November 2005 to September 2009, he served as Vice President of Finance and Principal Accounting Officer of Sirtris Pharmaceuticals, Inc., a biopharmaceutical company which GlaxoSmithKline plc purchased in 2008. He has over 13 years of experience in senior management roles leading growth-oriented biopharmaceutical companies through private and public financings, mergers and acquisitions and general financial operations. Mr. Brannelly started his biopharmaceutical career at Dyax Corporation as an Assistant Controller from September 1999 to May 2002, and subsequently moved on to positions of increasing responsibility at Zalicus Inc. (formerly CombinatoRx Inc.) from May 2002 to November 2005 and served as its Vice President, Finance and Treasurer, where he led Zalicus through the initial public offering process. He served as President of OvaScience, Inc. until September 2011. He earned his CPA license while working at several public accounting firms. Mr. Brannelly holds a Bachelors of Business Administration in Accounting from the University of Massachusetts at Amherst.
 
























I was told max compensation package as 115K..with car allowance and bonus. They pushed ownership in a start up. Backed out...good luck. Seems like the drug will do good, but salary in this industry is the only given. Bonus structure can change and range from 0-100K. As a start up with one drug, if they miss expectations, everything will change.
 






anonymous said:
I was told max compensation package as 115K..with car allowance and bonus. They pushed ownership in a start up. Backed out...good luck. Seems like the drug will do good, but salary in this industry is the only given. Bonus structure can change and range from 0-100K. As a start up with one drug, if they miss expectations, everything will change.
Click to expand...



U were told wrong.
 


















Top Bottom
Back
Quote